Cart
0
Get 20% Free Customization In This Report
Buy this report from - $4176

Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs, and Over-the-Counter Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Technology (Biologics, Cell Therapy, Gene Therapy, Drug Delivery, Small Molecule, and Others), Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, and Others), and Therapeutic Class (Anti-glaucoma, Anti-infection, Anti-inflammatory, and Anti-allergy) - Global Opportunity Analysis and Industry Forecast, 2017-2023

LI_17310
Pages: 351
Nov 2017 | 4887 Views
face gplus_n
Author's : Tanvi Sapatnekar & Garima Chandra
Tables: 221
Charts: 46
twit_n pr_n

Ophthalmic Drugs Market Overview:

Global Ophthalmic Drugs Market size was valued at $29,613 million in 2016, and is expected to reach $42,663 million by 2023, registering a CAGR of 5.3% from 2017 to 2023. Ophthalmic drugs are extensively used to treat glaucoma, cataract, diabetic retinopathy, and other ophthalmic disorders. Introduction of novel ocular drug delivery approaches in the market has driven the manufacturers to develop innovative therapeutic approaches for the treatment of ophthalmic disorders. According to the American Academy of Ophthalmology, 11 million people in the U.S. suffer from age-related macular degeneration (AMD), while approximately 10% of them are inflicted with wet AMD. Such trends in ophthalmic disorders across the globe contribute to the growth of the market.

The other key factors that boost the ophthalmic drug market size include high prevalence of glaucoma worldwide and rise in transition towards development of combination therapies for the treatment of glaucoma. In addition, the dynamics in the demographics across the globe contribute to the market growth. However, risk of side effects associated with ophthalmic drugs and the longer timelines required for novel ophthalmic drugs hamper this growth. Moreover, increase in investment by market players in emerging economies offers lucrative opportunities for market growth in near future.

Indication Segment Review

The ophthalmic drugs industry is segmented based on indication into dry eye, glaucoma, infection/inflammation/allergy, retinal disorders, and others. The retinal disorders segment is further classified into wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy, and others. Retinal disorders indication has registered significant growth rate, registering a CAGR of 5.8% from 2017 to 2023. The dry age-related macular degeneration segment accounts for the highest share among all the retinal disorders in 2016, and is expected to continue this trend throughout the forecast period.

Global Ophthalmic Drugs Market Segmentation: By Indication

Get more information on this report : Request Sample Pages

Dosage Form Segment Review

The ophthalmic drugs industry analysis is segmented based on dosage form into liquid, solid, semisolid, multicompartment drug delivery systems, and other ophthalmic drug forms. Liquid ophthalmic drug form segment accounted for the highest revenue in 2016, and is projected to maintain the trend throughout the forecast period. However, multicompartment drug delivery systems registered the highest CAGR of 8.0%. This is attributed to increase in development of novel ocular drug delivery approaches including nanoparticles, noisome, and dendrimers.

Get more information on this report : Request Sample Pages

Based on geography, the market is divided into North America, Europe, Asia-Pacific, and LAMEA. North America dominates the global market, accounting for 36% of the total market share in 2016, and is anticipated to lead throughout the forecast period. The report provides a comprehensive analysis of the key players operating in the global market such as Santen Pharmaceutical Co., Ltd., Bausch & Lomb Inc. (Valeant Pharmaceuticals International, Inc.), Shire Plc, Alcon (Novartis), Genentech, Inc. Allergan, Plc, Sun Pharmaceutical Industries Limited, Actavis Generics (Teva Pharmaceutical Industries Ltd.), Regeneron Pharmaceuticals, Inc., and Pfizer Inc.

Get more information on this report : Request Sample Pages

The other key players in the value chain include Abbott Medical Optics, Inc., Carl-Zeiss AG, Ellex Medical Lasers Ltd., Essilor International S.A., Hoya Corporation, Insight Vision Inc., Nidek Co.Ltd, Novagali Pharma S A, Topcon Corporation, and Ziemer Ophthalmic Systems AG.

Key Benefits

The study provides an in-depth analysis with the current trends and future estimations of the global ophthalmic drugs market to elucidate the imminent investment pockets.
Comprehensive analysis of the factors that drive and restrict the market growth is provided.
The quantitative analysis of the industry from 2016 to 2023 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of key segments of the industry is provided to understand the type of ophthalmic drugs used globally.
Key players and their strategies are analyzed to understand the competitive outlook of the market.

Ophthalmic Drugs Market Key Segments:

By Indication

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergy
  • Retinal Disorders
    • Wet Age-related Macular Degeneration
    • Dry Age-related Macular Degeneration
    • Diabetic Retinopathy
    • Others
  • Others

By Type

  • Prescription Drugs
  • Over-the-Counter Drugs

By Dosage Form

  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Other Ophthalmic Drug Forms

By Technology

  • Biologics
  • Cell Therapy
  • Gene Therapy
  • Drug Delivery
  • Small molecule
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Others

By Therapeutic Class

  • Anti-glaucoma
  • Anti-infection
  • Anti-inflammatory
  • Anti-allergy

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Turkey
    • Saudi Arabia
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTER’S FIVE FORCES ANALYSIS
3.4. MARKET SHARE ANALYSIS, 2016
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increase in focus of key players to develop combination therapies for the treatment of ophthalmic disorders
3.5.1.2. Rise in prevalence of ophthalmic disorders worldwide
3.5.1.3. Change in the demographics across the globe

3.5.2. Restraints

3.5.2.1. Longer timelines required for the development of ophthalmic drugs
3.5.2.2. Risk of side effects associated with ophthalmic drugs

3.5.3. Opportunity

3.5.3.1. Increase in investment by market players in the emerging economies

Chapter: 4 OPHTHALMIC DRUGS MARKET, BY INDICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. DRY EYE

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. GLAUCOMA

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. INFECTION/INFLAMMATION/ALLERGY

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. RETINAL DISORDERS

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.5.4. Wet age-related macular degeneration

4.5.4.1. Market size and forecast

4.5.5. Dry age-related macular degeneration

4.5.5.1. Market size and forecast

4.5.6. Diabetic retinopathy

4.5.6.1. Market size and forecast

4.5.7. Others

4.5.7.1. Market size and forecast

4.6. OTHERS

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

Chapter: 5 OPHTHALMIC DRUGS MARKET, BY TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. PRESCRIPTION DRUGS

5.2.1. Market size and forecast

5.3. OVER-THE-COUNTER DRUGS

5.3.1. Market size and forecast

Chapter: 6 OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. HOSPITAL PHARMACIES

6.2.1. Market size and forecast

6.3. DRUG STORES

6.3.1. Market size and forecast

6.4. ONLINE PHARMACIES

6.4.1. Market size and forecast

6.5. OTHERS

6.5.1. Market size and forecast

Chapter: 7 OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. LIQUID OPHTHALMIC DRUG FORMS

7.2.1. Market size and forecast

7.3. SEMISOLID OPHTHALMIC DRUG FORMS

7.3.1. Market size and forecast

7.4. SOLID OPHTHALMIC DRUG FORMS

7.4.1. Market size and forecast

7.5. MULTICOMPARTMENT DRUG DELIVERY SYSTEMS

7.5.1. Market size and forecast

7.6. OTHER OPHTHALMIC DRUG FORMS

7.6.1. Market size and forecast

Chapter: 8 OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. ANTI-INFLAMMATORY

8.2.1. Market size and forecast
8.2.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)
8.2.3. Steroids

8.3. ANTI-INFECTIVE

8.3.1. Market size and forecast
8.3.2. Antifungal drugs
8.3.3. Antibacterial drugs
8.3.4. Others

8.4. ANTI-GLAUCOMA

8.4.1. Market size and forecast
8.4.2. Beta blockers
8.4.3. Prostaglandin analogs
8.4.4. Others

8.5. ANTI-ALLERGY

8.5.1. Market size and forecast

Chapter: 9 OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY

9.1. OVERVIEW

9.1.1. Market size and forecast

9.2. BIOLOGICS

9.2.1. Market size and forecast

9.3. CELL THERAPY

9.3.1. Market size and forecast

9.4. GENE THERAPY

9.4.1. Market size and forecast

9.5. SMALL MOLECULE

9.5.1. Market size and forecast

9.6. DRUG DELIVERY

9.6.1. Market size and forecast

9.7. OTHERS

9.7.1. Market size and forecast

Chapter: 10 OPHTHALMIC DRUGS MARKET, BY REGION

10.1. OVERVIEW

10.1.1. Market size and forecast

10.2. NORTH AMERICA

10.2.1. Key market trends
10.2.2. Key growth factors and opportunities
10.2.3. Market size and forecast, by country
10.2.4. Market size and forecast, by indication
10.2.5. Market size and forecast, by type
10.2.6. Market size and forecast, by technology
10.2.7. Market size and forecast, by distribution channel
10.2.8. Market size and forecast, by dosage form
10.2.9. Market size and forecast, by therapeutic class

10.2.9.1. U.S., by indication
10.2.9.2. U.S., by type
10.2.9.3. U.S., by distribution channel
10.2.9.4. U.S., by dosage form
10.2.9.5. U.S., by technology
10.2.9.6. U.S., by therapeutic class
10.2.9.7. Canada, by indication
10.2.9.8. Canada, by type
10.2.9.9. Canada, by distribution channel
10.2.9.10. Canada, by dosage form
10.2.9.11. Canada, by technology
10.2.9.12. Canada, by therapeutic class
10.2.9.13. Mexico, by indication
10.2.9.14. Mexico, by type
10.2.9.15. Mexico, by distribution channel
10.2.9.16. Mexico, by dosage form
10.2.9.17. Mexico, by technology
10.2.9.18. Mexico, by therapeutic class

10.3. EUROPE

10.3.1. Key market trends
10.3.2. Key growth factors and opportunities
10.3.3. Europe Market size and forecast, by country
10.3.4. Market size and forecast, by indication
10.3.5. Market size and forecast, by type
10.3.6. Market size and forecast, by technology
10.3.7. Market size and forecast, by distribution channel
10.3.8. Market size and forecast, by dosage form
10.3.9. Market size and forecast, by therapeutic class

10.3.9.1. Germany, by indication
10.3.9.2. Germany, by type
10.3.9.3. Germany, by distribution channel
10.3.9.4. Germany, by dosage form
10.3.9.5. Germany, by technology
10.3.9.6. Germany, by therapeutic class
10.3.9.7. France, by indication
10.3.9.8. France, by type
10.3.9.9. France, by distribution channel
10.3.9.10. France, by dosage form
10.3.9.11. France, by technology
10.3.9.12. France, by therapeutic class
10.3.9.13. UK, by indication
10.3.9.14. UK, by type
10.3.9.15. UK, by distribution channel
10.3.9.16. UK, by dosage form
10.3.9.17. UK, by technology
10.3.9.18. UK, by therapeutic class
10.3.9.19. Italy, by indication
10.3.9.20. Italy, by type
10.3.9.21. Italy, by distribution channel
10.3.9.22. Italy, by dosage form
10.3.9.23. Italy, by technology
10.3.9.24. Italy, by therapeutic class
10.3.9.25. Spain, by indication
10.3.9.26. Spain, by type
10.3.9.27. Spain, by distribution channel
10.3.9.28. Spain, by dosage form
10.3.9.29. Spain, by technology
10.3.9.30. Spain, by therapeutic class
10.3.9.31. Rest of Europe, by indication
10.3.9.32. Rest of Europe, by type
10.3.9.33. Rest of Europe, by distribution channel
10.3.9.34. Rest of Europe, by dosage form
10.3.9.35. Rest of Europe, by technology
10.3.9.36. Rest of Europe, by therapeutic class

10.4. ASIA-PACIFIC

10.4.1. Key market trends
10.4.2. Key growth factors and opportunities
10.4.3. Asia-Pacific Market size and forecast, by country
10.4.4. Market size and forecast, by indication
10.4.5. Market size and forecast, by type
10.4.6. Market size and forecast, by technology
10.4.7. Market size and forecast, by distribution channel
10.4.8. Market size and forecast, by dosage form
10.4.9. Market size and forecast, by therapeutic class

10.4.9.1. Japan, by indication
10.4.9.2. Japan, by type
10.4.9.3. Japan, by distribution channel
10.4.9.4. Japan, by dosage form
10.4.9.5. Japan, by technology
10.4.9.6. Japan, by therapeutic class
10.4.9.7. China, by indication
10.4.9.8. China, by type
10.4.9.9. China, by distribution channel
10.4.9.10. China, by dosage form
10.4.9.11. China, by technology
10.4.9.12. China, by therapeutic class
10.4.9.13. India, by indication
10.4.9.14. India, by type
10.4.9.15. India, by distribution channel
10.4.9.16. India, by dosage form
10.4.9.17. India, by technology
10.4.9.18. India, by therapeutic class
10.4.9.19. Australia, by indication
10.4.9.20. Australia, by type
10.4.9.21. Australia, by distribution channel
10.4.9.22. Australia, by dosage form
10.4.9.23. Australia, by technology
10.4.9.24. Australia, by therapeutic class
10.4.9.25. South Korea, by indication
10.4.9.26. South Korea, by type
10.4.9.27. South Korea, by distribution channel
10.4.9.28. South Korea, by dosage form
10.4.9.29. South Korea, by technology
10.4.9.30. South Korea, by therapeutic class
10.4.9.31. Rest of Asia-Pacific, by indication
10.4.9.32. Rest of Asia-Pacific, by type
10.4.9.33. Rest of Asia-Pacific, by distribution channel
10.4.9.34. Rest of Asia-Pacific, by dosage form
10.4.9.35. Rest of Asia-Pacific, by technology
10.4.9.36. Rest of Asia-Pacific, by therapeutic class

10.5. LAMEA

10.5.1. Key market trends
10.5.2. Key growth factors and opportunities
10.5.3. LAMEA Market size and forecast, by country
10.5.4. Market size and forecast, by indication
10.5.5. Market size and forecast, by type
10.5.6. Market size and forecast, by technology
10.5.7. Market size and forecast, by distribution channel
10.5.8. Market size and forecast, by dosage form
10.5.9. Market size and forecast, by therapeutic class

10.5.9.1. Brazil, by indication
10.5.9.2. Brazil, by type
10.5.9.3. Brazil, by distribution channel
10.5.9.4. Brazil, by dosage form
10.5.9.5. Brazil, by technology
10.5.9.6. Brazil, by therapeutic class
10.5.9.7. South Africa, by indication
10.5.9.8. South Africa, by type
10.5.9.9. South Africa, by distribution channel
10.5.9.10. South Africa, by dosage form
10.5.9.11. South Africa, by technology
10.5.9.12. South Africa, by therapeutic class
10.5.9.13. Turkey, by indication
10.5.9.14. Turkey, by type
10.5.9.15. Turkey, by distribution channel
10.5.9.16. Turkey, by dosage form
10.5.9.17. Turkey, by technology
10.5.9.18. Turkey, by therapeutic class
10.5.9.19. Saudi Arabia, by indication
10.5.9.20. Saudi Arabia, by type
10.5.9.21. Saudi Arabia, by distribution channel
10.5.9.22. Saudi Arabia, by dosage form
10.5.9.23. Saudi Arabia, by technology
10.5.9.24. Saudi Arabia, by therapeutic class
10.5.9.25. Rest of LAMEA, by indication
10.5.9.26. Rest of LAMEA, by type
10.5.9.27. Rest of LAMEA, by distribution channel
10.5.9.28. Rest of LAMEA, by dosage form
10.5.9.29. Rest of LAMEA, by technology
10.5.9.30. Rest of LAMEA, by therapeutic class

Chapter: 11 COMPANY PROFILES

11.1. ALLERGAN PLC

11.1.1. Company overview
11.1.2. Company snapshot
11.1.3. Operating business segments
11.1.4. Product portfolio
11.1.5. Business performance
11.1.6. Key strategic moves and developments

11.2. F. HOFFMANN-LA ROCHE AG (GENENTECH, INC.)

11.2.1. Company overview
11.2.2. Company snapshot
11.2.3. Operating business segments
11.2.4. Product portfolio
11.2.5. Business performance
11.2.6. Key strategic moves and developments

11.3. NOVARTIS AG (ALCON-A DIVISION OF NOVARTIS)

11.3.1. Company overview
11.3.2. Company snapshot
11.3.3. Operating business segments
11.3.4. Product portfolio
11.3.5. Business performance
11.3.6. Key strategic moves and developments

11.4. PFIZER INC.

11.4.1. Company overview
11.4.2. Company snapshot
11.4.3. Operating business segments
11.4.4. Product portfolio
11.4.5. Business performance
11.4.6. Key strategic moves and developments

11.5. REGENERON PHARMACEUTICALS INC.

11.5.1. Company overview
11.5.2. Company snapshot
11.5.3. Operating business segments
11.5.4. Product portfolio
11.5.5. Business performance
11.5.6. Key strategic moves and developments

11.6. SANTEN PHARMACEUTICAL CO., LTD.

11.6.1. Company overview
11.6.2. Company snapshot
11.6.3. Operating business segments
11.6.4. Product portfolio
11.6.5. Business performance
11.6.6. Key strategic moves and developments

11.7. SHIRE PLC

11.7.1. Company overview
11.7.2. Company snapshot
11.7.3. Operating business segments
11.7.4. Product portfolio
11.7.5. Business performance
11.7.6. Key strategic moves and developments

11.8. SUN PHARMACEUTICAL INDUSTRIES LIMITED

11.8.1. Company overview
11.8.2. Company snapshot
11.8.3. Operating business segments
11.8.4. Product portfolio
11.8.5. Business performance
11.8.6. Key strategic moves and developments

11.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.( ACTAVIS GENERICS)

11.9.1. Company overview
11.9.2. Company snapshot
11.9.3. Operating business segments
11.9.4. Product portfolio
11.9.5. Business performance
11.9.6. Key strategic moves and developments

11.10. VALEANT PHARMACEUTICAL INTERNATIONAL, INC. (BAUSCH & LOMB INC.)

11.10.1. Company overview
11.10.2. Company snapshot
11.10.3. Operating business segments
11.10.4. Product portfolio
11.10.5. Business performance
11.10.6. Key strategic moves and developments

LIST OF TABLES

TABLE 1. NOVARTIS OPHTHALMOLOGIC PIPELINE PORTFOLIO, JULY 2011
TABLE 2. GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 3. OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY REGION, 2016-2023 ($MILLION)
TABLE 4. OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY REGION, 2016-2023 ($MILLION)
TABLE 5. OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY REGION, 2016-2023 ($MILLION)
TABLE 6. OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY REGION, 2016-2023 ($MILLION)
TABLE 7. OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY TYPE, 2016-2023 ($MILLION)
TABLE 8. OPHTHALMIC DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2016-2023 ($MILLION)
TABLE 9. OPHTHALMIC DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2016-2023 ($MILLION)
TABLE 10. OPHTHALMIC DRUGS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2016-2023 ($MILLION)
TABLE 11. OPHTHALMIC DRUGS MARKET FOR OTHER, BY REGION, 2016-2023 ($MILLION)
TABLE 12. OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
TABLE 13. GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 14. PRESCRIPTION OPHTHALMIC DRUGS OFFERED BY BAUSCH + LOMB
TABLE 15. PRESCRIPTION OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 16. OPHTHALMIC DRUGS AVAILABLE OVER THE COUNTER FOR THE TREATMENT OF DRY EYE
TABLE 17. OVER-THE-COUNTER OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. GLOBAL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 19. OPHTHALMIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2016-2023 ($MILLION)
TABLE 20. OPHTHALMIC DRUGS MARKET FOR DRUG STORES, BY REGION, 2016-2023 ($MILLION)
TABLE 21. OPHTHALMIC DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2016-2023 ($MILLION)
TABLE 22. OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
TABLE 23. GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 24. OPHTHALMIC DRUGS ADMINISTERED IN LIQUID FORMS
TABLE 25. LIQUID OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 26. OPHTHALMIC DRUGS ADMINISTERED IN SEMISOLID FORMS
TABLE 27. SEMISOLID OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 28. VARIOUS TYPES OF SOLID OPHTHALMIC DRUG FORMS
TABLE 29. SOLID OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 30. MULTICOMPARTMENT DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 31. OTHER OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 32. GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 33. OPHTHALMIC DRUGS MARKET FOR ANTI-INFLAMMATORY, BY REGION, 2016-2023 ($MILLION)
TABLE 34. OPHTHALMIC DRUGS MARKET FOR ANTI-INFECTIVE, BY REGION, 2016-2023 ($MILLION)
TABLE 35. OPHTHALMIC DRUGS MARKET FOR ANTI-GLAUCOMA, BY REGION, 2016-2023 ($MILLION)
TABLE 36. OPHTHALMIC DRUGS MARKET FOR ANTI-ALLERGY, BY REGION, 2016-2023 ($MILLION)
TABLE 37. GLOBAL OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 38. FDA-APPROVED OCULAR BIOLOGICS
TABLE 39. OPHTHALMIC DRUGS MARKET FOR BIOLOGICS, BY REGION, 2016-2023 ($MILLION)
TABLE 40. OPHTHALMIC DRUGS MARKET FOR CELL THERAPY, BY REGION, 2016-2023 ($MILLION)
TABLE 41. OPHTHALMIC DRUGS MARKET FOR GENE THERAPY, BY REGION, 2016-2023 ($MILLION)
TABLE 42. OPHTHALMIC DRUGS MARKET FOR SMALL MOLECULE, BY REGION, 2016-2023 ($MILLION)
TABLE 43. OPHTHALMIC DRUGS MARKET FOR DRUG DELIVERY, BY REGION, 2016-2023 ($MILLION)
TABLE 44. OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
TABLE 45. OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 46. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 47. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 48. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 49. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 50. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 51. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 52. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 53. U.S. OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 54. U.S. OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 55. U.S. OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 56. U.S. OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 57. U.S. OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 58. U.S. OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 59. CANADA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 60. CANADA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 61. CANADA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 62. CANADA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 63. CANADA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 64. CANADA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 65. MEXICO OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 66. MEXICO OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 67. MEXICO OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 68. MEXICO OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 69. MEXICO OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 70. MEXICO OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 71. EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 72. EUROPE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 73. EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 74. EUROPE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 75. EUROPE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 76. EUROPE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 77. EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 78. GERMANY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 79. GERMANY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 80. GERMANY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 81. GERMANY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 82. GERMANY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 83. GERMANY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 84. FRANCE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 85. FRANCE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 86. FRANCE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 87. FRANCE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 88. FRANCE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 89. FRANCE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 90. UK OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 91. UK OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 92. UK OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 93. UK OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 94. UK OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 95. UK OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 96. ITALY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 97. ITALY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 98. ITALY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 99. ITALY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 100. ITALY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 101. ITALY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 102. SPAIN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 103. SPAIN OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 104. SPAIN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 105. SPAIN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 106. SPAIN OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 107. SPAIN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 108. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 109. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 110. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 111. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 112. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 113. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 114. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 115. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 116. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 117. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 118. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 119. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 120. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 121. JAPAN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 122. JAPAN OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 123. JAPAN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 124. JAPAN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 125. JAPAN OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 126. JAPAN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 127. CHINA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 128. CHINA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 129. CHINA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 130. CHINA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 131. CHINA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 132. CHINA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 133. INDIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 134. INDIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 135. INDIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 136. INDIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 137. INDIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 138. INDIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 139. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 140. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 141. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 142. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 143. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 144. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 145. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 146. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 147. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 148. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 149. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 150. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 151. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 152. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 153. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 154. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 155. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 156. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 157. LAMEA OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 158. LAMEA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 159. LAMEA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 160. LAMEA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 161. LAMEA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 162. LAMEA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 163. LAMEA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 164. BRAZIL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 165. BRAZIL OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 166. BRAZIL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 167. BRAZIL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 168. BRAZIL OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 169. BRAZIL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 170. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 171. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 172. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 173. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 174. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 175. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 176. TURKEY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 177. TURKEY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 178. TURKEY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 179. TURKEY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 180. TURKEY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 181. TURKEY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 182. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 183. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 184. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 185. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 186. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 187. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 188. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 189. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 190. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 191. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 192. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 193. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 194. ALLERGAN: COMPANY SNAPSHOT
TABLE 195. ALLERGEN: OPERATING SEGMENTS
TABLE 196. ALLERGAN: PRODUCT PORTFOLIO
TABLE 197. ROCHE: COMPANY SNAPSHOT
TABLE 198. ROCHE: OPERATING SEGMENT
TABLE 199. ROCHE: PRODUCT PORTFOLIO
TABLE 200. NOVARTIS: COMPANY SNAPSHOT
TABLE 201. NOVARTIS: OPERATING SEGMENTS
TABLE 202. NOVARTIS: PRODUCT PORTFOLIO
TABLE 203. PFIZER: COMPANY SNAPSHOT
TABLE 204. PFIZER: OPERATING SEGMENTS
TABLE 205. PFIZER: PRODUCT PORTFOLIO
TABLE 206. REGENERON: COMPANY SNAPSHOT
TABLE 207. REGENERON: PRODUCT PORTFOLIO
TABLE 208. SANTEN PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 209. SANTEN PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 210. SANTEN PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 211. SHIRE: COMPANY SNAPSHOT
TABLE 212. SHIRE: PRODUCT PORTFOLIO
TABLE 213. SUN PHARMA: COMPANY SNAPSHOT
TABLE 214. SUN PHARMA: OPERATING SEGMENTS
TABLE 215. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 216. TEVA: COMPANY SNAPSHOT
TABLE 217. TEVA: OPERATING SEGMENTS
TABLE 218. TEVA: PRODUCT PORTFOLIO
TABLE 219. VALEANT: COMPANY SNAPSHOT
TABLE 220. VALEANT: OPERATING SEGMENTS
TABLE 221. VALEANT: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. GLOBAL OPHTHALMIC DRUGS MARKET SNAPSHOT, 2016-2023
FIGURE 2. OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023
FIGURE 3. MARKET SEGMENTATION
FIGURE 4. TOP INVESTMENT POCKETS
FIGURE 5. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 6. TOTAL NUMBER OF STRATEGIES
FIGURE 7. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 8. HIGH BARGAINING POWER OF BUYERS
FIGURE 9. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10. HIGH THREAT OF NEW ENTRANTS
FIGURE 11. HIGH THREAT OF SUBSTITUTION
FIGURE 12. MODERATE COMPETITIVE RIVALRY
FIGURE 13. MARKET SHARE ANALYSIS, 2016
FIGURE 14. DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 15. PREVALENT CASES OF AMD IN THE U.S., 2010
FIGURE 16. GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016
FIGURE 17. ALLERGAN: NET SALES, 2014-2016 ($MILLION)
FIGURE 18. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 19. ROCHE: NET-SALES, 2014-2016 ($MILLION)
FIGURE 20. ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 21. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 22. NOVARTIS: NET SALES, 2014-2016 ($MILLION)
FIGURE 23. NOVARTIS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 24. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25. ALCON: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. ALCON: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 27. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 28. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 29. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 30. REGENERON: NET SALES, 2014-2016 ($MILLION)
FIGURE 31. SANTEN PHARMACEUTICAL: NET SALES, 2015-2017 ($MILLION)
FIGURE 32. SANTEN PHARMACEUTICAL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33. SANTEN PHARMACEUTICAL: REVENUE SHARE BY PRODUCT CATEGORY, 2017 (%)
FIGURE 34. SANTEN PHARMACEUTICAL: REVENUE SHARE BY GEOGRAPHY, 2017(%)
FIGURE 35. SHIRE: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. SHIRE: REVENUE SHARE BY PRODUCT CATEGORY, 2016 (%)
FIGURE 37. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 38. SUN PHARMA: NET SALES, 2015-2017 ($MILLION)
FIGURE 39. SUN PHARMA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 40. SUN PHARMA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 41. TEVA: NET SALES, 2014-2016 ($MILLION)
FIGURE 42. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 43. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 44. VALEANT: NET SALES, 2014-2016 ($MILLION)
FIGURE 45. VALEANT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 46. VALEANT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

 

Ophthalmic therapeutic treatment is gaining traction, owing to the increase in number of people suffering from eye ailments, such as eye infections, allergies, and dry eye, each year throughout the world. Thus, significant increase in incidence of glaucoma, cataract, and retinal disorders drives the market growth. In addition, the need for ocular drugs used in the treatment of diabetic retinopathy has increased exponentially, owing to a major proportion of individuals suffering from diabetes.

Prescription ophthalmic drugs accounted the highest revenue in 2016, and are anticipated to lead throughout the forecast period. Small molecule technology for developing ophthalmic drugs dominated the market in 2016, and is set to continue the trend throughout the forecast period. Moreover, ophthalmic disorders are preferably treated by medications administered through topical or systemic route. Topical applications of ophthalmic drugs are incorporated in the treatment of patients suffering from eye ailments, owing to the ease of administration via topical ocular drugs, low cost, and patient compliance. Increase in focus on developing combination therapies for treatment of ophthalmic disorders, prevalence of ophthalmic disorders, and rise in geriatric population are anticipated to drive the growth of the ophthalmic drugs market. However, longer timelines required for the approval of novel ophthalmic drugs and side effects associated with these hamper the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Request sample

OR

Purchase Full Report of
Ophthalmic Drugs Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $4176
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo